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Nerve Growth Factor (NGF): Physiological Functions 
and Regulation of Its Synthesis 
D . L I N D H O L M 1 , R . H E U M A N N , G . D . B O R A S I O and H . T H O E N E N 
1 Introduction 
The physiological role of N G F as a neurotrophic factor in the peripheral nervous 
system is well established. N G F is essential for the development and maintenance 
of specific functions of peripheral sympathetic and neural-crest derived sensory 
neurons. N G F acts as a retrograde messenger between the target organs and the 
innervating neurons. The regionally different quantities of N G F in target tissues 
reflect the density of innervation by NGF-responsive neurons, which transport 
N G F in membrane-confined compartments to the perikaryon after N G F is bound 
via specific membrane receptors. Although the physiological function of N G F is 
well documented and a large number of NGF-specific effects on target neurons 
have been identified, there are two main questions which remain to be elucidated, 
namely the nature of the second messenger(s) evolving from the binding of N G F 
to its receptor and the mode of regulation of N G F synthesis in the target tissues. A 
better understanding of this regulation would provide the prerequisite for a 
rational approach to the pharmacological modification of N G F synthesis. This is 
of particular interest because it has recently become apparent that N G F is essential 
for the preservation of the function of the cholinergic neurons of the basal forebrain 
nuclei. These neurons are consistently affected in Alzheimers's disease and their 
impaired function seems to be largely responsible for the cognitive deficits of this 
disease. 
2 Physiological Functions of NGF 
Earlier work on N G F was mainly focussed on the role of N G F in embryonic 
development and differentiation of the peripheral nervous system (Levi-Mon-
talcini 1987). N G F has been shown to regulate the survival of peripheral sym-
pathetic and neural-crest derived sensory neurons during restricted periods of 
development (cf. Levi-Montalcini and Angeletti 1968; Greene and Shooter 1980; 
Thoenen and Barde 1980). This has been conclusively demonstrated in exper-
iments on neonatal rodents where administration of anti-NGF antibodies leads to 
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enhanced cell death in the NGF-responsive neuronal population, whereas ex-
ogenous N G F can rescue neurons which normally would die during the period of 
natural cell death. In addition, N G F is also required for differentiation and 
maintenance of function of the peripheral sympathetic and sensory neurons in 
adult life. Thus, N G F has been shown to regulate synthesis of specific enzymes 
which are involved in neurotransmitter production, such as tyrosine hydroxylase 
and dopamine /^-hydroxylase as well as a series of neuron-specific peptides (cf. 
Otten 1984; Johnson E.M. et al. 1986; Thoenenetal. 1987). In the peripheral target 
fields N G F is synthesized in very low amounts and is retrogradely transported to 
the cell bodies of NGF-responsive neurons after being taken up via specific cell 
surface receptors (cf. Schwab et al. 1982). It has also been shown that the density 
of innervation of target organs by NGF-responsive neurons correlates with the 
levels of N G F and its mRNA (Korsching and Thoenen 1983; Heumannetal. 1984; 
Shelton and Reichardt 1984). Moreover, interruption of the retrograde axonal 
transport of N G F following axotomy or by pharmacological interference (e.g. 
colchicine treatment which results in disassembly of microtubuli) leads to 
degenerative changes in the NGF-responsive neurons, demonstrating that N G F 
acts as a retrograde messenger between the periphery and the innervating neurons 
(cf.Thoenen etal. 1987). 
In contrast to sympathetic neurons in the peripheral nervous system, central 
adrenergic neurons neither respond to N G F nor carry N G F receptors (Konkol et 
al. 1978; Schwab et al. 1979). However, evidence for a trophic role of N G F in the 
central nervous system became apparent when it was shown that the cholinergic 
neurons of the basal forebrain nuclei express N G F receptors and exhibit specific 
retrograde transport of N G F (Schwab et al. 1979; Seiler and Schwab 1984). The 
cholinergic neurons have also been shown to respond to N G F with an increase in 
the levels of choline acetyltransferase (ChAT), the enzyme responsible for 
synthesis of the cholinergic neurotransmitter acetylcholine. This has been shown 
both in neonatal rats (Gnahn et al. 1983), in aggregate cultures of fetal forebrain 
(Honegger and Lenoir 1982), and in adult rats after partial fimbria lesions, i.e. of 
the septo-hippocampal connection (Hefti et al. 1984). The cell bodies of the 
cholinergic neurons are situated in the medial septal nuclei, in the diagonal band 
of Broca and in the basal nuclei of Meynert. Their fiber tracts project to the 
hippocampus, neocortex and olfactory bulb (cf. Cuello and Sofroniew 1984) and 
these innervated areas exhibit relatively high levels of N G F and NGF-mRNA as 
compared to other brain regions (Korsching et al. 1985; Whittemore et al. 1986; 
Shelton and Reichardt 1986). In analogy to the situation in the peripheral nervous 
system, there is a close correlation between the levels of N G F and its mRNA and 
the density of cholinergic innervation. Even within the rat hippocampus there are 
differences between N G F levels of various regions, e.g. the CA3, CA4 and dentate 
gyrus region have higher levels of N G F protein compared with the CA1-CA2 
region and this is reflected in the density of cholinergic innervation (cf. Korsching 
1986; Thoenen et al. 1987). Recent autoradiographic receptor binding studies on 
sections from adult rat brain have clearly demonstrated the presence of N G F 
receptors on these cholinergic neurons (Riopelle et al. 1987; Raivich and 
Kreutzberg 1987). Moreover, N G F levels and ChAT activity in rat hippocampus 
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increase in parallel during postnatal development, further supporting a role of 
N G F in this septo-hippocampal system (Auburger et al. 1987). Likewise, fimbria 
lesion experiments have shown that exogenous N G F administrated through an 
infusion pump can rescue cholinergic neurons of the basal forebrain nuclei which 
would otherwise degenerate following the transection (Hefti 1986; Kromer 1987; 
Williamset al. 1986). 
3 Mechanism(s) of Action of NGF 
Although many actions of N G F on target neurons have been described, the overall 
mechanism by which N G F exerts its effects is still unknown. This also holds true 
for the most important long-term effect of N G F , namely its survival-promoting 
activity on NGF-responsive neurons. N G F receptors on sensory (Sutter et al. 1979) 
and sympathetic neurons (Godfrey and Shooter 1986) and on PC 12 pheo-
chromocytoma cells (Hosang and Shooter 1985) have been identified and antibodies 
to the N G F receptor have been produced (Chandler et al. 1984; Ross et al. 1984). 
Moreover, binding studies have shown the existence of both high- and low-affinity 
N G F receptors on target cells which are encoded by the same mRNA. However, 
the mechanism for conversion between the two forms is not known but the 
high-affinity receptor seems to be responsible for most of the biological action of 
N G F , at least in PC12 cells (Green et al. 1986). Recently, both human and rat N G F 
receptors have been cloned (Johnson D. et al. 1986; Radeke et al. 1987) and the 
molecular data demonstrate that the N G F receptor belongs to a novel class of 
membrane receptors which lack an intrinsic tyrosine kinase activity. N G F is also 
known not to affect neuronal proliferation which is in contrast to most growth 
factors which have a mitogenic activity on their target cells (cf. Thoenen et al. 1987). 
Previous studies have shown that intracellular microinjection of N G F into the 
cytoplasm of PC 12 cells, bypassing the receptor, fails to elicit differentiation which 
is readily seen with N G F in the culture medium (Heumann et al. 1981). Conversely, 
microinjected, function-blocking, anti-NGF antibodies do not inhibit N G F action 
on PC 12 cells. These studies led to the conclusion that N G F acts by a distinct second 
messenger system, the nature of which remains to be elucidated (Heumann et al. 
1981). The results of recent studies have suggested a role for the ras oncogene 
product in N G F signal transduction. Introduction of purified, activated, ras 
protein into PC 12 cells can elicit differentiation (Bar-Sagi and Feramisco 1985), 
and microinjected, anti-ras antibodies are able to block the effect of N G F on these 
cells (Hagag et al. 1986). The exact site of action of ras or of ras-like proteins in the 
signal transduction cascade induced by N G F is not known. Further downstream, 
transcriptional activators are most probably involved in regulating NGF-specific 
gene expression. Interestingly, N G F (Greenberg et al. 1985) as well as ras protein 
(Stacey et al. 1987) are known to transiently increase expression of the c-fos 
proto-oncogene product which is thought to be involved in transcriptional 
regulation. Milbrandt (1987) has recently described another putative transcrip-
tional activator gene whose transcription is strongly induced in PC 12 cells by 
short-term N G F treatment. 
Nerve Growth Factor 25 
4 Regulation of NGF Synthesis and Implications for Treatment of Alzheimer's 
Disease 
In Alzheimer's disease the cholinergic neurons of the basal forebrain nuclei are 
consistently affected and there is an atrophy and /or loss of these neurons during the 
course of this disease (Coyle et al. 1983; Pearson et al. 1983). Moreover, the 
impaired synthesis of acetylcholine is one of the earliest detectable signs of 
Alzheimer's disease and correlates well with the cognitive deficits observed 
(Francis et al. 1985). In view of the fact that these cholinergic neurons are also the 
target of N G F in the central nervous system, the hypothesis was put forward that 
N G F could play a role in this disease (Hefti and Weiner 1986). The idea that 
Alzheimer's disease results from an insufficient supply of N G F for these neurons 
has recently been disputed by Goedert and co-workers (1986). These authors 
demonstrated that the levels of NGF-mRN A in the cerebral cortex of patients with 
Alzheimer's disease are not different from the corresponding levels found in 
age-matched controls. Nevertheless, the following observations support the notion 
that pharmacological amounts of N G F are of potential value in treatment of 
Alzheimer's disease by supporting the cholinergic neurons undergoing atrophy or 
degeneration. Thus, it has been demonstrated that chronic administration of N G F 
over a period of 4 weeks can improve memory function, as shown by behavioural 
tests, and can counteract cholinergic cell body atrophy observed in a subpopulation 
of aged rats (Fischer et al. 1987). Moreover, studies on septo-hippocampal lesions 
clearly show that exogenous N G F has a beneficial effect in preventing cholinergic 
cell degeneration in the septal area after a transection of the fimbria (Hefti 1986; 
Kromer 1987; Williams et al. 1986). Likewise, N G F injections (Will and Hefti 
1985) or transplantation of fetal cholinergic neurons into the hippocampus 
(Dunnett et al. 1982; Gage and Björklund 1986) can improve both learning and 
memory deficits observed in rats after such a lesion. 
In view of these findings it seems justified to consider N G F supplementation 
as a possible therapeutic approach for the treatment of patients suffering from 
Alzheimer's disease. This could be achieved by either local administration of 
recombinant human N G F , of peptides with NGF-like functions or by enhancing 
endogenous N G F synthesis by pharmacological agents. However, a prerequisite 
for such an intervention is a better understanding of the physiological mechanisms 
by which N G F is regulated in vivo. Recent studies in the peripheral nervous system 
have shown that specific polypeptide factors are involved in the control of N G F 
synthesis in the nonneuronal cells. Using the rat sciatic nerve as a model system 
under conditions of degeneration and regeneration after a nerve lesion, we were 
able to show that macrophages play an important role in N G F regulation 
(Heumann et al. 1987; Thoenen et al. 1988). Interleukin-1, a lymphokine produced 
by these cells, was found to be the responsible agent increasing NGF-mRN A levels 
in the nonneuronal cells (Lindholm et al. 1987). Recent studies indicate that the 
action of IL-1 involves activation of phospholipase A2 and that IL-1 has a dual 
effect on NGF-mRN A. Thus, IL-1 enhances N G F gene transcription and also 
increases the stability of NGF-mRNA in cultured sciatic nerve fibroblasts 
(Lindholm et al. 1988). 
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The studies on the regulation of N G F synthesis in the central nervous system 
are less advanced compared with the peripheral nervous system. We have recently 
obtained evidence that IL-1 and other mesenchymal growth factors can influence 
NGF-mRNA levels in cultured rat astrocytes. We are currently studying the 
complex interplay of various growth factors in controlling NGF-mRNA synthesis 
in the central nervous system both in vivo and in vitro. Moreover, since it has very 
recently been reported that hippocampal neurons can also express NGF-mRNA 
(Rennert and Heinrich 1986; Ayer-LeLievre et al. 1988) this adds a new dimension 
to studies concerned with the regulation of N G F synthesis in the central nervous 
system. 
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